Dollar Hedging May Push Euro to $1.30, Morgan Stanley Says
The team led by David Adams, who has one of the most bullish euro calls on Wall Street, says an advance above $1.30 for the euro 'is not a risk to be underestimated' as doubts about the dollar's safe-haven status prompt investors to protect against further volatility. This is an even higher prediction than the $1.27 level they expect by the end of next year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
Ashmore Group (LON:ASHM) investors are sitting on a loss of 39% if they invested five years ago
Ashmore Group Plc (LON:ASHM) shareholders will doubtless be very grateful to see the share price up 33% in the last quarter. But if you look at the last five years the returns have not been good. In fact, the share price is down 58%, which falls well short of the return you could get by buying an index fund. It's worthwhile assessing if the company's economics have been moving in lockstep with these underwhelming shareholder returns, or if there is some disparity between the two. So let's do just that. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement. During the five years over which the share price declined, Ashmore Group's earnings per share (EPS) dropped by 19% each year. The share price decline of 16% per year isn't as bad as the EPS decline. The relatively muted share price reaction might be because the market expects the business to turn around. The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers). Dive deeper into Ashmore Group's key metrics by checking this interactive graph of Ashmore Group's earnings, revenue and cash flow. What About Dividends? It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. In the case of Ashmore Group, it has a TSR of -39% for the last 5 years. That exceeds its share price return that we previously mentioned. The dividends paid by the company have thusly boosted the total shareholder return. A Different Perspective Ashmore Group provided a TSR of 11% over the year (including dividends). That's fairly close to the broader market return. The silver lining is that the share price is up in the short term, which flies in the face of the annualised loss of 7% over the last five years. We're pretty skeptical of turnaround stories, but it's good to see the recent share price recovery. It's always interesting to track share price performance over the longer term. But to understand Ashmore Group better, we need to consider many other factors. Case in point: We've spotted 3 warning signs for Ashmore Group you should be aware of, and 2 of them make us uncomfortable. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on British exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
7 minutes ago
- Yahoo
PHSC Full Year 2025 Earnings: UK£0.012 loss per share (vs UK£0.022 profit in FY 2024)
PHSC (LON:PHSC) Full Year 2025 Results Key Financial Results Revenue: UK£3.22m (down 15% from FY 2024). Net loss: UK£126.2k (down by 151% from UK£248.8k profit in FY 2024). UK£0.012 loss per share (down from UK£0.022 profit in FY 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period PHSC shares are down 14% from a week ago. Risk Analysis It's necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with PHSC (at least 1 which is a bit unpleasant), and understanding these should be part of your investment process. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
7 minutes ago
- Yahoo
Carl Zeiss Meditec (ETR:AFX) shareholders have endured a 62% loss from investing in the stock three years ago
If you love investing in stocks you're bound to buy some losers. Long term Carl Zeiss Meditec AG (ETR:AFX) shareholders know that all too well, since the share price is down considerably over three years. Sadly for them, the share price is down 63% in that time. Now let's have a look at the company's fundamentals, and see if the long term shareholder return has matched the performance of the underlying business. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). During the three years that the share price fell, Carl Zeiss Meditec's earnings per share (EPS) dropped by 16% each year. This reduction in EPS is slower than the 28% annual reduction in the share price. So it seems the market was too confident about the business, in the past. The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image). Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here. A Different Perspective While the broader market gained around 23% in the last year, Carl Zeiss Meditec shareholders lost 16% (even including dividends). Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 7% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. It's always interesting to track share price performance over the longer term. But to understand Carl Zeiss Meditec better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Carl Zeiss Meditec , and understanding them should be part of your investment process. For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on German exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
